Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin

Fineline Cube Mar 11, 2026
Company Drug

Keymed Biosciences Initiates CMG901 Phase III – AstraZeneca Triggers $45 Million Milestone for Claudin 18.2 ADC

Fineline Cube Mar 11, 2026
Company Drug

Shenzhen Beike Initiates First Chinese Stem Cell Study for Systemic Lupus Erythematosus

Fineline Cube Jan 24, 2025

China-based stem cell specialist Shenzhen Beike Biotechnology Co., Ltd has announced the initiation of a...

Company Medical Device

Accuray’s Tomo C System Completes Treatment of First 100 Patients in China

Fineline Cube Jan 24, 2025

US-based medical device firm Accuray Inc. (NASDAQ: ARAY) has announced the completion of treating the...

Company Deals

Ascentage Pharma Prices US IPO at USD 17.25 per ADS

Fineline Cube Jan 24, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...

Company Drug

United Laboratories’ Biosimilar Semaglutide Accepted for Review by China’s NMPA

Fineline Cube Jan 24, 2025

Hong Kong-listed United Laboratories International Holdings Ltd (HKG: 3933) has announced that its market filing...

Company Drug

Beijing Aosaikang’s ASKB589 Shows Promise in Phase I/II Study for Gastric Cancer

Fineline Cube Jan 24, 2025

China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has unveiled the latest results from a...

Company Drug

Biogen’s Higher-Dose Spinraza Regimen Under Review by FDA and EMA

Fineline Cube Jan 24, 2025

US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has submitted supplemental New Drug Applications (sNDAs) to the...

Company Deals

Novo Nordisk Partners with IMMvention on BACH1 Program for Sickle Cell Disease

Fineline Cube Jan 24, 2025

Denmark-based Novo Nordisk A/S (NYSE: NVO) has entered into a strategic collaboration and license agreement...

Company

Zai Lab’s ZL-1310 Granted Orphan Drug Designation by FDA for SCLC

Fineline Cube Jan 23, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced that the US Food...

Company Deals

Simnova, Orna Expand Partnership to Develop BCMA-Targeted RNA Therapies

Fineline Cube Jan 23, 2025

Shanghai Simnova Biotech Co., Ltd. (Simnova), an affiliate of Simcere Investment Group, has expanded its...

Company

Johnson & Johnson Reports Q4 Growth, Projects 2025 Sales Outlook

Fineline Cube Jan 23, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has released its Q4 2024 financial results, reporting...

Company Drug

YolTech Initiates Study for YOLT-204 in Transfusion-Dependent Beta-Thalassemia

Fineline Cube Jan 23, 2025

Shanghai-based YolTech Therapeutics, a biotech startup specializing in lipid nanoparticle delivery and gene editing, has...

Company Drug

Haichang Bio’s siRNA Drug HC016 Cleared for US Clinical Trials

Fineline Cube Jan 23, 2025

China-based Zhejiang Haichang Biotech Co., Ltd has announced that its siRNA drug, HC016 complex lipid,...

Company Deals

iMBIORAY Raises RMB 100 Million in Series A+ for NK Cell Therapies

Fineline Cube Jan 23, 2025

Hangzhou-based cell therapy specialist iMBIORAY has reportedly raised close to RMB 100 million (USD 13.7...

Company Drug Medical Device

Abbott Labs Posts Q4 Growth, Projects Strong 2025 Outlook

Fineline Cube Jan 23, 2025

US-based Abbott Laboratories (NYSE: ABT) has released its Q4 2024 financial results, reporting an 8.8%...

Company Deals

Shenzhen TargetRx Raises $50M in Series C Financing for Global Clinical Trials

Fineline Cube Jan 23, 2025

China-based Shenzhen TargetRx, Inc., a developer of small-molecule kinase inhibitors, has announced the completion of...

Company Drug

Haisco’s HSK44459 Approved for Clinical Trials in Behcet’s Disease

Fineline Cube Jan 23, 2025

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving clinical trial approval from...

Company Deals

Fosun’s Plan to Take Henlius Private Fails After Shareholder Vote

Fineline Cube Jan 23, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its plan...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Approval for DMD Clinical Trial

Fineline Cube Jan 23, 2025

China-based gene therapy specialist Belief BioMed Inc. (BBM) has announced receiving clinical trial approval from...

Company Medical Device

Roche’s cobas liat STI Assay Panels Gain FDA Approval and CLIA Waiver

Fineline Cube Jan 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced receiving approval from the US...

Company Drug

United Laboratories’ UBT251 Approved for Phase II Trials in Chronic Kidney Disease

Fineline Cube Jan 23, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced receiving approval from the...

Posts pagination

1 … 188 189 190 … 632

Recent updates

  • Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin
  • Keymed Biosciences Initiates CMG901 Phase III – AstraZeneca Triggers $45 Million Milestone for Claudin 18.2 ADC
  • SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas’ XOSPATA Fails Phase III Primary Endpoint in Frontline AML – FLT3 Inhibitor Misses OS Benefit vs. Midostaurin

Company Drug

Keymed Biosciences Initiates CMG901 Phase III – AstraZeneca Triggers $45 Million Milestone for Claudin 18.2 ADC

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.